CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 51 enrolled
Drug / intervention
enadenotucirev +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02636036
NCT02636036Phase 1Completed
CompareCT.gov

A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Akamis Bio·interventional·Posted Dec 21, 2015·Updated Nov 9, 2021

In Brief

A Phase 1 clinical trial evaluating enadenotucirev and nivolumab for Colorectal Cancer and 2 related conditions. Completed, enrolled 51 participants across 6 sites.

Detailed Summary

This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase), not responding to standard therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Syneos Health

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 21, 2015
Enrollment StartJan 25, 2016
Primary CompletionOct 8, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 10.5 years ago

Interventions

enadenotucirevbiological

nivolumabbiological